A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS).
A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS).
复制标题
年龄对局灶性节段性肾小球硬化症 (FSGS) 中阿达木单抗吸收和消除的可能影响。
DOI：
10.1007/s00228-015-1973-1
复制
发表时间：
2016
影响因子：
2.9
通讯作者：
Joy,MelanieS
中科院分区：
文献类型：
--
作者：
Ternant,David;Paintaud,Gilles;Trachtman,Howard;Gipson,DebbieS;Joy,MelanieS
Adalimumab (Humira®), an anti-TNF-α monoclonal antibody, leads to highly variable serum concentrations between patients [1, 2]. Although an important portion of this variability may be due to the subcutaneous route of administration, the variability of adalimumab absorption kinetics following a subcutaneous injection has never been reported.In the Novel Therapies for Resistant FSGS (FONT) phase I study [3, 4], patients with focal segmental glomerulosclerosis (FSGS) were randomized into two arms that evaluated adalimumab [4] or rosiglitazone [3]. We report a description of adalimumab PK in FSGS patients using population compartmental modelling, with a focus on evaluation of adalimumab absorption kinetics.
